background
data
avail
rate
characterist
thromboembol
complic
hospit
patient
method
studi
consecut
symptomat
patient
laboratoryproven
admit
univers
hospit
milan
itali
primari
outcom
thromboembol
complic
includ
venou
thromboembol
vte
ischem
stroke
acut
coronari
syndrom
ac
myocardi
infarct
mi
secondari
outcom
overt
dissemin
intravascular
coagul
dic
result
includ
patient
median
age
year
men
requir
intens
care
icu
thromboprophylaxi
use
icu
patient
gener
ward
thromboembol
event
occur
close
case
ci
correspond
cumul
rate
icu
gener
ward
half
thromboembol
event
diagnos
within
h
hospit
admiss
fortyfour
patient
underw
vte
imag
test
vte
confirm
comput
tomographi
pulmonari
angiographi
ctpa
perform
patient
correspond
total
pulmonari
embol
confirm
ctpa
rate
ischem
stroke
acsmi
respect
overt
dic
present
patient
conclus
high
number
arteri
particular
venou
thromboembol
event
diagnos
within
h
admiss
high
rate
posit
vte
imag
test
among
patient
test
suggest
urgent
need
improv
specif
vte
diagnost
strategi
investig
efficaci
safeti
thromboprophylaxi
ambulatori
patient
novel
sever
acut
respiratori
syndrom
coronaviru
caus
coronaviru
diseas
led
unpreced
global
health
crisi
date
death
confirm
case
fatal
rate
estim
high
countri
clinic
manifest
absent
mild
substanti
proport
subject
test
posit
bilater
pneumonia
main
find
hospit
patient
least
initi
present
seriou
condit
requir
advanc
medic
support
intens
care
bilater
pneumonia
system
inflamm
endotheli
dysfunct
coagul
activ
acut
respiratori
distress
syndrom
multiorgan
failur
describ
key
featur
sever
sign
myocardi
injuri
present
least
one
quarter
sever
case
http
receiv
april
receiv
revis
form
april
accept
april
postul
high
mortal
observ
among
patient
may
partli
due
unrecogn
pulmonari
embol
pe
pulmonari
situ
thrombosi
estim
risk
arteri
particular
venou
thromboembol
complic
still
preliminari
depend
local
diagnost
pharmacolog
prevent
strategi
better
understand
thromboembol
risk
help
optim
diagnost
strategi
guid
design
conduct
random
control
trial
vte
prevent
studi
describ
rate
characterist
venou
arteri
thromboembol
complic
consecut
patient
admit
larg
academ
hospit
milan
itali
sinc
begin
outbreak
retrospect
cohort
studi
includ
data
consecut
adult
symptomat
patient
laboratoryproven
admit
larg
univers
hospit
humanita
clinic
research
hospit
rozzano
milan
lombardi
itali
sinc
februari
studi
approv
institut
ethic
committe
patient
gave
standard
written
consent
use
data
aim
describ
rate
venou
arteri
thromboembol
complic
hospit
patient
electron
medic
record
serv
sourc
data
collect
demograph
clinic
laboratori
treatment
outcom
data
extract
anonym
form
two
physician
potenti
disagr
concern
interpret
find
done
collabor
third
physician
primari
outcom
composit
venou
arteri
thromboembol
event
encompass
vte
cardiovascular
event
vte
includ
pulmonari
embol
pe
deep
vein
thrombosi
dvt
diagnos
accept
imag
test
period
consid
present
analysi
vte
screen
strategi
among
patient
place
studi
site
vte
imag
test
perform
subject
sign
symptom
dvt
unexplain
clinic
worsen
respiratori
function
primarili
assess
use
pao
fio
ratio
rapid
increas
ddimer
level
twopoint
compress
ultrasonographi
cu
use
intens
care
unit
icu
wholeleg
ultrasound
perform
symptomat
patient
gener
ward
cardiovascular
event
includ
acut
coronari
syndromemyocardi
infarct
ischem
stroke
report
treat
physician
medic
chart
secondari
outcom
overt
dissemin
intravascular
coagul
dic
review
electron
medic
chart
aboratori
find
platelet
count
ddimer
prothrombin
time
fibrinogen
level
patient
retrospect
calcul
intern
societi
thrombosi
haemostasi
isth
score
overt
dic
consid
present
score
greater
describ
characterist
studi
popul
use
count
percentag
categor
variabl
use
appropri
measur
central
tendenc
dispers
describ
continu
variabl
rate
event
accompani
confid
interv
ci
calcul
close
case
defin
patient
discharg
dead
analysi
thromboembol
complic
diagnos
thromboembol
event
cumul
rate
calcul
whole
studi
popul
includ
patient
still
hospit
univari
logist
regress
perform
ascertain
effect
age
likelihood
patient
die
hospit
probabl
death
across
age
depict
visual
miss
valu
report
variabl
jasp
spss
v
serv
data
analysi
extract
data
consecut
patient
laboratoryproven
admit
median
age
year
men
total
patient
test
day
initi
hospit
admiss
eight
patient
test
first
week
hospit
six
week
hospit
patient
admit
hospit
first
day
outbreak
belong
latter
group
total
patient
requir
intens
care
remain
patient
admit
gener
ward
patient
requir
intens
care
initi
admit
gener
ward
median
day
median
length
stay
icu
day
tabl
summar
baselin
characterist
studi
popul
includ
overal
durat
hospit
record
total
inhospit
death
correspond
inhospit
mortal
rate
among
close
case
death
occur
median
day
hospit
admiss
fig
depict
probabl
inhospit
death
across
age
odd
ratio
per
year
increas
ci
variat
ddimer
level
among
survivor
nonsurvivor
display
tabl
icu
patient
receiv
thromboprophylaxi
lowmolecularweight
heparin
dosag
weightadjust
patient
therapeut
two
patient
ambulatori
treatment
direct
oral
anticoagul
total
patient
admit
gener
ward
receiv
initi
inhospit
thromboprophylaxi
prophylact
dosag
use
patient
treat
intermediatedosag
thromboprophylaxi
receiv
therapeuticdos
anticoagul
includ
continu
ambulatori
treatment
atrial
fibril
prior
vte
thromboembol
event
occur
close
case
rate
ci
among
close
case
correspond
cumul
rate
eight
event
occur
icu
patient
ci
correspond
cumul
rate
twenti
event
occur
patient
gener
ward
ci
correspond
cumul
rate
tabl
report
detail
descript
thromboembol
event
tabl
fortyfour
patient
underw
vte
imag
test
posit
test
total
patient
ten
event
pulmonari
embol
ctpa
posit
patient
vte
vte
event
diagnos
within
h
hospit
admiss
nine
patient
receiv
anticoagul
treatment
one
patient
diagnos
subsegment
pe
occur
anticoagul
prophylaxi
ischem
stroke
diagnos
patient
icu
gener
ward
one
patient
develop
stroke
acut
pe
patient
stroke
primari
reason
hospit
acut
coronari
syndromemyocardi
infarct
diagnos
four
patient
icu
one
gener
ward
repres
primari
reason
hospit
patient
total
patient
met
laboratori
criteria
overt
dic
six
patient
men
one
requir
intens
care
four
solid
hematolog
cancer
bleed
complic
record
two
patient
thromboembol
event
dvt
ischem
stroke
tabl
seven
patient
overt
dic
die
hospit
perform
comprehens
analysi
rate
time
characterist
venou
arteri
thromboembol
complic
among
consecut
patient
admit
larg
univers
hospit
milan
itali
result
indic
thromboembol
complic
may
repres
integr
part
clinic
pictur
alreadi
present
time
initi
hospit
admiss
incid
howev
may
highli
underestim
due
low
number
specif
imag
test
perform
remain
unclear
whether
increas
intens
thrombosi
prophylaxi
select
patient
may
provid
clinic
benefit
patient
without
confirm
acut
vte
intervent
manag
trial
conduct
improv
prevent
diagnosi
treatment
thrombot
complic
patient
previous
coagul
cardiac
biomark
describ
elev
patient
reflect
inflammatori
statu
character
coagul
activ
endotheli
dysfunct
predictor
death
show
despit
use
anticoagul
prophylaxi
rate
venou
arteri
thromboembol
complic
hospit
patient
remark
approxim
inde
alreadi
high
chronic
renal
dysfunct
present
previous
report
baselin
anamnest
estim
glomerular
filtrat
rate
mlmin
activ
cancer
defin
presenc
metastat
termin
cancer
activ
cancer
therapi
prior
month
ace
angiotensinconvert
enzym
fig
probabl
inhospit
death
across
age
perform
logist
regress
ascertain
effect
age
likelihood
patient
die
hospit
odd
ratio
ci
figur
depict
probabl
inhospit
death
across
age
analysi
restrict
close
case
dead
discharg
time
analysi
figur
may
repres
underestim
actual
valu
postul
base
four
key
find
vte
activ
search
patient
ii
one
third
vte
imag
test
posit
iii
half
venou
arteri
thromboembol
event
diagnos
within
first
h
hospit
admiss
repres
often
first
manifest
iv
vast
major
pe
event
unquestion
radiologicalanatom
perspect
diagnosi
incident
observ
rate
thrombot
event
line
recent
preliminari
analys
although
sever
patient
use
thromboprophylaxi
across
studi
heterogen
may
influenc
estim
recent
dutch
paper
symptomat
vte
diagnos
total
cumul
rate
patient
receiv
thromboprophylaxi
intens
care
mainli
consist
pe
n
dutch
studi
minor
patient
experienc
arteri
thrombot
event
n
accord
chines
studi
preval
vte
routin
vte
screen
although
detail
type
time
screen
provid
valu
appear
much
higher
rate
symptomat
vte
event
observ
thromboprophylaxi
trial
exceed
patient
receiv
anticoagul
therapi
thromboprophylaxi
line
observ
patient
sepsi
shock
recent
analysi
french
group
show
rate
thromboembol
complic
patient
ard
much
higher
observ
histor
control
group
ard
patient
despit
anticoagul
show
major
thrombot
complic
venou
primarili
repres
isol
pe
consist
proport
posit
ctpa
total
ctpa
perform
appear
higher
posit
cu
total
cu
perform
indirect
evid
one
may
postul
case
suspect
pe
execut
cu
may
logist
feasibl
give
less
use
inform
delay
ctpa
test
suggest
use
higher
prophylaxi
dosag
may
improv
outcom
patient
result
analysi
suggest
lower
threshold
suspicion
perform
vte
imag
test
may
reason
even
upon
admiss
earli
phase
observ
least
half
thromboembol
event
diagnos
within
first
h
admiss
therefor
prevent
inhospit
thromboprophylaxi
would
otherwis
inadequ
dose
presenc
acut
vte
routin
thromboprophylaxi
recommend
ambulatori
patient
acut
medic
ill
respiratori
symptom
postul
administr
lowmolecularweight
heparin
earlier
phase
infect
may
exert
posit
effect
term
thrombosi
prevent
also
reduc
system
pulmonari
inflamm
limit
viral
invas
sever
countri
number
patient
manag
ambulatori
basi
also
logist
reason
burden
thromboembol
complic
patient
unknown
data
repres
condit
probabl
therefor
care
interpret
suggest
may
repres
underestim
largescal
issu
requir
rapid
answer
random
control
trial
ovid
trial
plan
studi
whether
prophylacticdos
enoxaparin
vs
treatment
may
reduc
earli
allcaus
mortal
unplan
hospit
adult
symptomat
ambulatori
patient
indic
receiv
anticoagul
acknowledg
limit
studi
retrospect
analysi
conduct
larg
univers
hospit
therefor
possibl
reflect
manag
strategi
diagnost
facil
nonacadem
institut
patient
includ
analysi
diagnos
one
red
zone
european
outbreak
start
may
influenc
patient
outcom
global
experi
diseas
avail
yet
also
execut
frequenc
imag
test
hospit
perspect
could
confirm
whether
thromboembol
event
contribut
tabl
median
ddimer
level
survivor
nonsurvivor
hospit
analysi
restrict
close
case
ddimer
level
present
median
express
ngml
icu
intens
care
unit
substanti
dramat
mortal
autopsi
routin
perform
patient
inde
show
ddimer
level
marker
inflamm
coagul
activ
rapidli
increas
nonsurvivor
cours
hospit
overt
dic
present
patient
fatal
almost
case
hospit
patient
character
substanti
inhospit
mortal
high
rate
thromboembol
complic
rapidli
increas
ddimer
level
observ
nonsurvivor
reflect
inflammatori
procoagul
state
high
number
arteri
particular
venou
thromboembol
event
diagnos
within
h
admiss
high
rate
posit
vte
imag
test
among
patient
test
suggest
urgent
need
improv
specif
vte
diagnost
strategi
investig
efficaci
safeti
thromboprophylaxi
ambulatori
patient
corrado
lodigiani
receiv
congress
travel
payment
bayer
healthcar
daiichisankyo
boehring
ingelheim
novonordisk
takeda
honoraria
daiichisankyo
takeda
novonordisk
boehring
ingelheim
bayer
healthcar
aspen
italfarmaco
stefano
barco
receiv
congress
travel
payment
daiichisankyo
bayer
healthcar
honoraria
bayer
healthcar
leopharma
author
disclos
potenti
conflict
interest
present
studi
fund
